Agoglia Luciana, Peixoto Helena, Cardoso Ana Carolina, Barbosa Lívia, Victer Cecília S X L, Carneiro Sueli, Salles Gil F, Villela-Nogueira Cristiane A, Chindamo Maria Chiara
Department of Internal Medicine, Faculty of Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ Brazil; Section of Gastroenterology, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brazil.
Department of Internal Medicine, Faculty of Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ Brazil.
An Bras Dermatol. 2025 May-Jun;100(3):456-461. doi: 10.1016/j.abd.2024.07.013. Epub 2025 Mar 12.
Psoriasis is an inflammatory skin disease associated with Metabolic Syndrome (MetS), Steatotic Liver Disease (SLD) and cardiovascular risk. However, the effect of anti-inflammatory therapy on cardiovascular risk is uncertain.
To determine the relationship between anti-inflammatory therapy and subclinical atherosclerosis in individuals with psoriasis, using the gold standard carotid-femoral Pulse Wave Velocity (cf-PWV) measurement. Additionally, to evaluate the association between cf-PWV, steatosis and Advanced Fibrosis (AF) using Transient Elastography (TE) by Fibroscan®.
Cross-sectional study including psoriasis patients submitted to cf-PWV and TE. Steatosis was defined as a controlled attenuation parameter ≥ 275 dB/m, AF as liver stiffness measurement ≥ 10 kPa, and increased Aortic Stiffness (AoS) as cf-PWV ≥ 10 m/s. Significant cumulative methotrexate dose was ≥ 1500 mg (MTX1500). Logistic regression analysis evaluated the independent variables associated with increased AoS.
Eighty patients were included (mean age 56.2 ± 11.5-years, 57.5% female, BMI 28.6 ± 5.3 kg/m). Prevalences of MetS, diabetes mellitus, dyslipidemia, systemic arterial hypertension, steatosis and AF were 57.5%, 40.0%, 67.5%, 70.0%, 50.0% and 16.3%, respectively. MTX1500 was present in 45%, immunobiological treatment in 33.8%, and cf-PWV ≥ 10 m/s in 21.2%. On logistic regression analysis, age was independently related to cf-PWV ≥ 10 m/s (OR = 1.21; 95% CI 1.06‒1.38; p = 0.003) and MTX1500 was a protective cardiovascular factor (OR = 0.18; 95% CI 0.038‒0.87; p = 0.033). No association was observed between steatosis, AF or immunobiological therapy and cf-PWV ≥10 m/s.
Sample size.
In patients with psoriasis, increased AoS was associated with age, but not with steatosis or AF. A protective cardiovascular effect of MTX was found in a psoriasis population with a high prevalence of MetS and its components.
银屑病是一种与代谢综合征(MetS)、脂肪性肝病(SLD)和心血管风险相关的炎症性皮肤病。然而,抗炎治疗对心血管风险的影响尚不确定。
使用金标准颈动脉-股动脉脉搏波速度(cf-PWV)测量法,确定银屑病患者抗炎治疗与亚临床动脉粥样硬化之间的关系。此外,使用Fibroscan®的瞬时弹性成像(TE)评估cf-PWV、脂肪变性和晚期纤维化(AF)之间的关联。
横断面研究,纳入接受cf-PWV和TE检查的银屑病患者。脂肪变性定义为受控衰减参数≥275 dB/m,AF定义为肝脏硬度测量值≥10 kPa,主动脉僵硬度(AoS)增加定义为cf-PWV≥10 m/s。显著累积甲氨蝶呤剂量≥1500 mg(MTX1500)。逻辑回归分析评估与AoS增加相关的独立变量。
纳入80例患者(平均年龄56.2±11.5岁,57.5%为女性,BMI 28.6±5.3 kg/m²)。MetS、糖尿病、血脂异常、系统性动脉高血压、脂肪变性和AF的患病率分别为57.5%、40.0%、67.5%、70.0%、50.0%和16.3%。45%的患者存在MTX1500,33.8%接受免疫生物治疗,21.2%的患者cf-PWV≥10 m/s。逻辑回归分析显示,年龄与cf-PWV≥10 m/s独立相关(OR = 1.21;95%CI 1.06‒1.38;p = 0.003),MTX1500是一个保护性心血管因素(OR = 0.18;95%CI